Neurovascular and neuroimaging effects of the hallucinogenic serotonin receptor agonist psilocin in the rat brain
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The development of pharmacological magnetic resonance imaging (phMRI) has presented the opportunity for investigation of the neurophysiological effects of drugs in vivo. Psilocin, a hallucinogen metabolised from psilocybin, was recently reported to evoke brain region-specific, phMRI signal changes in humans. The present study investigated the effects of psilocin in a rat model using phMRI and then probed the relationship between neuronal and haemodynamic responses using a multimodal measurement preparation. Psilocin (2 mg/kg or 0.03 mg/kg i.v.) or vehicle was administered to rats (N=6/group) during either phMRI scanning or concurrent imaging of cortical blood flow and recording of local field potentials. Compared to vehicle controls psilocin (2 mg/kg) evoked phMRI signal increases in a number of regions including olfactory and limbic areas and elements of the visual system. PhMRI signal decreases were seen in other regions including somatosensory and motor cortices. Investigation of neurovascular coupling revealed that whilst neuronal responses (local field potentials) to sensory stimuli were decreased in amplitude by psilocin administration, concurrently measured haemodynamic responses (cerebral blood flow) were enhanced. The present findings show that psilocin evoked region-specific changes in phMRI signals in the rat, confirming recent human data. However, the results also suggest that the haemodynamic signal changes underlying phMRI responses reflect changes in both neuronal activity and neurovascular coupling. This highlights the importance of understanding the neurovascular effects of pharmacological manipulations for interpreting haemodynamic neuroimaging data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 1×
“This approach has recently been applied to psilocybin, the active constituent of “magic” mushrooms; which is of interest due to its potential utility in treating affective disorders (Carhart-Harris et al., 2012a, 2012b; Grob et al., 2011; Vollenweider and Kometer, 2010).”
MethodNeural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018 · cited 2×
“Vollenweider et al., 1998) but whether and how this action is relevant to its therapeutic effects is unclear.”
BackgroundShmuel, A., Augath, M., Oeltermann, A., & Logothetis, N. K. (2006) · Nature Neuroscience · doi:10.1038/nn1675 · Cited by 898
Hemodynamic Signals Correlate Tightly with Synchronized Gamma Oscillations
Niessing, J., Ebisch, B., Schmidt, K. E., Niessing, M., Singer, W., & Galuske, R. A. W. (2005) · Science · doi:10.1126/science.1110948 · Cited by 806 · cited 2×
“Against a background of reduced neuronal oscillatory power in this ‘delta’ range, haemodynamic response signals have been shown elsewhere to increase (Niessing et al., 2005), providing an additional explanation for the enhancement of stimulus-evoked haemodynamic responses observed here following psilocin treatment.”
BackgroundThe neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723 · cited 2×
“This approach has recently been applied to psilocybin, the active constituent of “magic” mushrooms; which is of interest due to its potential utility in treating affective disorders (Carhart-Harris et al., 2012a, 2012b; Grob et al., 2011; Vollenweider and Kometer, 2010).”
BackgroundMethodInterspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics
Boxenbaum, H. (1982) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01062336 · Cited by 648 · cited 1×
“Without scaling for interspecies pharmacokinetic differences, however, there may not be direct concordance between the two doses (Boxenbaum, 1982; Lin, 1998).”
BackgroundBiophysical and Physiological Origins of Blood Oxygenation Level-Dependent fMRI Signals
Kim, S.-G., & Ogawa, S. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.23 · Cited by 547 · cited 1×
“Indeed, such processes may be highly dependent on differences between anatomical regions, and local synaptic input, as well as a number of factors (Kim and Ogawa, 2012; Lauritzen et al., 2012).”
BackgroundRive, M. M., van Rooijen, G., Veltman, D. J., .Phillips, M. L., Schene, A. H., & Ruhé, H. G. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.07.018 · Cited by 481 · cited 2×
“Furthermore, these findings may have implications for neuroimaging studies in clinical cohorts where serotonergic anomalies are known to exist (Rive et al., 2013).”
BackgroundThe pharmacology of psilocybin
Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. (2002) · Addiction Biology · doi:10.1080/1355621021000005937 · Cited by 465 · cited 1×
“In vivo, psilocybin undergoes first pass metabolism to psilocin, the active metabolite thought to account for most of the psychotropic effects of psilocybin administration (Hasler et al., 1997; Passie et al., 2002).”
Background
Cited by
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression
Roseman, L., Demetriou, L., Wall, M. B., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.041 · Cited by 230
“Other comparisons should be considered exploratory (QIDS, STAI and in-scanner state anxiety).”
InfluentialAltered network hub connectivity after acute LSD administration
Müller, F., Dolder, P. C., Schmidt, A., Liechti, M. E., & Borgwardt, S. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.03.005 · Cited by 174
Classical hallucinogens and neuroimaging: A systematic review of human studies
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.10.026 · Cited by 107
Müller, F., Liechti, M. E., Lang, U. E., & Borgwardt, S. (2018) · Progress in Brain Research · doi:10.1016/bs.pbr.2018.08.004 · Cited by 31
Metadata
- Authors
- Spain, A., Howarth, C., Khrapitchev, A. A., Sharp, T., Sibson, N. R., & Martin, C.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 99
- Pages
- 210-220
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W878533373
- Cited by
- 37
- References
- 17
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neurovascular and neuroimaging effects of the hallucinogenic serotonin receptor agonist psilocin in the rat brain. https://app.cochat.ai/papers/10.1016/j.neuropharm.2015.07.018
- The paper
- Spain, A., Howarth, C., Khrapitchev, A. A., Sharp, T., Sibson, N. R., & Martin, C. (2015). Neurovascular and neuroimaging effects of the hallucinogenic serotonin receptor agonist psilocin in the rat brain. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2015.07.018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.